echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hesco subsidiary FTP-198 was approved for clinical trials

    Hesco subsidiary FTP-198 was approved for clinical trials

    • Last Update: 2020-12-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The drug will be used in clinical trials for idynic pulmonary fibrosis.
    FTP-198 is a class 1 innovative chemical developed by our company for the treatment of idiotic pulmonary fibrosis (IPF).
    IPF is a chronic, aggressive fibrosis lung disease with unknown epathy, which can cause peripheral pulmonary fibrosis remodeling, leading to respiratory failure, the incidence of which increases with age, and is common in people aged 60 to 70 years, and is the most common idynogenic interstitity pneumonia.
    IPF diagnosis after the median survival of 2 to 5 years, high mortality rate, is the respiratory system of the incurable diseases of the Company and all members of the Board of Directors to ensure that the information disclosure content is true, accurate, complete, no false records, misleading statements or major omissions.
    of 2 diseases.
    , IPF has not been a significantly effective treatment, so there is an urgent need for a new treatment that is effective and more to-bearable.
    The target mechanism of this product is clear, there is the potential for expandable adaptive disorders, in addition to fibrosis and tumors, but also includes angiogenesic, autoimmune diseases, inflammation, NASH, neurodegenerative lesions and other adaptive disorders, the company will be based on the situation of the species or will carry out the above-mentioned expansion of adaptive disease research and development.
    FTP-198 passed the Australian Ethics Review in January 2020 and conducted a single/multiple dose, randomized, double-blind, placebo-controlled, dose incremental study of healthy people in the first quarter of 2020.
    based on current results, it is expected to be a potential best-in-class treatment for idiotreatable pulmonary fibrosis (IPF).
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.